The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Update on the AML treatment landscape
Thorsten Braun
• 29 Jun 2020
Thorsten Braun, MD, PhD, Hôpitaux de Paris, Université Paris 13, Bobigny, France, outlines the current landscape and future directions in treating patients with acute myeloid leukemia (AML). Dr Braun discusses targeted therapies, liposomal daunorubicin/cytarabine and venetoclax-based therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
